Search Result

Results for "

alcoholic fatty liver disease

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (1) Acyltransferase (1) Adiponectin Receptor (1) AMPK (4) Autophagy (1) Cannabinoid Receptor (1) Caspase (1) Endogenous Metabolite (5) Ferroptosis (1) FXR (1) iGluR (1) Isotope-Labeled Compounds (1) MDM-2/p53 (1) Na+/K+ ATPase (1) NF-κB (2) NOD-like Receptor (NLR) (1) P2X Receptor (1) PPAR (3) Pyroptosis (1) Stearoyl-CoA Desaturase (SCD) (1) TGF-β Receptor (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (5) Infection (3) Inflammation/Immunology (9) Metabolic Disease (17) Neurological Disease (1)

By Targets:

17β-HSD (1)

Acyltransferase (1)

Adiponectin Receptor (1)

AMPK (4)

Autophagy (1)

Cannabinoid Receptor (1)

Caspase (1)

Endogenous Metabolite (5)

Ferroptosis (1)

FXR (1)

iGluR (1)

Isotope-Labeled Compounds (1)

MDM-2/p53 (1)

Na+/K+ ATPase (1)

NF-κB (2)

NOD-like Receptor (NLR) (1)

P2X Receptor (1)

PPAR (3)

Pyroptosis (1)

Stearoyl-CoA Desaturase (SCD) (1)

TGF-β Receptor (1)

Toll-like Receptor (TLR) (1)

By Research Areas:

Cancer (3)

Cardiovascular Disease (5)

Infection (3)

Inflammation/Immunology (9)

Metabolic Disease (17)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Free Fatty Acid Receptor Fatty Acid Synthase (FASN) LXR FATP FABP FAAH

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N9182

Zeaxanthin dipalmitate Physalien	Adiponectin Receptor P2X Receptor Autophagy	Inflammation/Immunology
Zeaxanthin dipalmitate (Physalien) is a wolfberry-derived carotenoid, has anti-inflammatory and anti-oxidative stress effects. Zeaxanthin dipalmitate directly interact with p2X7 receptor (K_d=81.2 nM) and adiponectin receptor 1 (AdipoR1; K_d=533 nM) in a positive dose-dependent manner. Zeaxanthin dipalmitate restores mitochondrial autophagy functions suppressed by ethanol intoxication. Zeaxanthin dipalmitate can be used in the research of alcoholic fatty liver disease (AFLD) and retinitis pigmentosa (RP) .

HY-160004

PXL770

AMPK Others

PXL770 is a direct AMP kinase activator. PXL770 can be used in the research of non-alcoholic fatty liver disease (NAFLD) .

PXL770	AMPK	Others
PXL770 is a direct AMP kinase activator. PXL770 can be used in the research of non-alcoholic fatty liver disease (NAFLD) .

HY-111179

ML261	Others	Inflammation/Immunology
ML261 is a hepatic lipid droplets formation inhibitor with an IC₅₀ value of 69.7 nM. ML261 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and inflammation .

HY-W013215

Adrenic acid cis-7,10,13,16-Docosatetraenoic acid	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
Adrenic Acid (cis-7,10,13,16-Docosatetraenoic acid) is a naturally polyunsaturated fatty acid in the adrenal gland, brain, kidney, and vasculature. Adrenic Acid can regulate the vascular tone in arteries of the adrenal cortex. Adrenic Acid also is an inflammation enhancer in non-alcoholic fatty liver disease .

HY-N9921

Antcin A	Pyroptosis NOD-like Receptor (NLR)	Inflammation/Immunology
Antcin A is a potent NLRP3 inhibitor that inhibits the assembly and activation of the NLRP3 inflammasome. Antcin A can inhibit Kupffer cell pyroptosis and has liver protective activity. Antcin A can be used to study inflammation, such as non-alcoholic fatty liver disease .

HY-126967A

1-Palmitoyl-sn-glycerol 3-phosphate 1-P-GPA	Others	Metabolic Disease
1-Palmitoyl-sn-glycerol 3-phosphate (1-P-GPA) is an endogenous metabolite. 1-Palmitoyl-sn-glycerol 3-phosphate can be used for the research of non‐alcoholic fatty liver disease .

HY-W337335

1-Palmitoyl-sn-glycerol 3-phosphate sodium salt 1-P-GPA sodium salt	Endogenous Metabolite	Metabolic Disease
1-Palmitoyl-sn-glycerol 3-phosphate (sodium salt) (1-P-GPA (sodium salt)) is an endogenous metabolite. 1-Palmitoyl-sn-glycerol 3-phosphate (sodium salt) can be used in the study of non-alcoholic fatty liver disease .

HY-W018392

Mono-(2-ethylhexyl) phthalate Maximum Cited Publications 6 Publications Verification MEHP; Phthalic acid mono-2-ethylhexyl ester	Endogenous Metabolite	Metabolic Disease
Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD) .

HY-116444A

16-HETE	Na+/K+ ATPase	Cardiovascular Disease Inflammation/Immunology
16-HETE is arachidonic acid metabolite through subterminal hydroxylation by cytochrome P-450. 16-HETE exhibits vasodilatory and PMN inhibitory effects and serves as biomarker for early stages of non-alcoholic fatty liver disease .

HY-N0592

Demethyleneberberine	NF-κB AMPK	Infection Metabolic Disease Inflammation/Immunology Cancer
Demethyleneberberine is a natural mitochondria-targeted antioxidant. Demethyleneberberine alleviates mice colitis and inhibits the inflammatory responses by inhibiting NF-κB pathway and regulating the balance of Th cells. Demethyleneberberine could serve as a AMPK activator for treating non-alcoholic fatty liver disease (NAFLD) .

HY-N0592A

Demethyleneberberine chloride	NF-κB AMPK	Infection Metabolic Disease Inflammation/Immunology Cancer
Demethyleneberberine chloride is a natural mitochondria-targeted antioxidant. Demethyleneberberine chloride alleviates mice colitis and inhibits the inflammatory responses by inhibiting NF-κB pathway and regulating the balance of Th cells. Demethyleneberberine chloride could serve as a AMPK activator for researching non-alcoholic fatty liver disease (NAFLD) .

HY-103479

GOAT-IN-1	Acyltransferase	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
GOAT-IN-1 is an inhibitor of ghrelin O-acyltransferase (GOAT), which could be useful for the prophylaxis or treatment of obesity, diabetes, hyperlipidemia, metabolic, non-alcoholic fatty liver, steatohepatitis, sarcopenia, appetite control, alcohol/narcotic dependence, Alzheimer’s disease, Parkinson’s disease, cerebrovascular dementia, cerebral apoplexy, cerebral infarction, cardic disease, some kind of tumors.

HY-151959

FXR agonist 4	FXR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
FXR agonist 4 (compound 10a) is an agonist of farnesoid X receptor (FXR) with an EC₅₀ value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD) .

HY-P10133

PRDX3(103-112) SO3 modified, human

Ferroptosis Metabolic Disease

PRDX3(103-112) SO3 modified, human is a marker of ferroptosis, and can be used for liver diseases study .

PRDX3(103-112) SO3 modified, human	Ferroptosis	Metabolic Disease
PRDX3(103-112) SO3 modified, human is a marker of ferroptosis, and can be used for liver diseases study .

HY-139230

OLHHA	Cannabinoid Receptor PPAR	Metabolic Disease
OLHHA is a dual CB1 receptor antagonist and PPARα agonist. OLHHA also is a alcohol intake inhibitor with an EC₅₀ value of 0.2 mg/kg. OLHHA reduces both hepatic lipid accumulation and circulating triglyceride levels. OLHHA shows anti-steatotic activity and has the potential for the research of non-alcoholic fatty liver disease (NAFLD) .

HY-W018392S

Mono-(2-ethylhexyl) phthalate-d4 MEHP-d₄; Phthalic acid mono-2-ethylhexyl ester-d₄	Isotope-Labeled Compounds	Metabolic Disease
Mono-(2-ethylhexyl) phthalate-d₄ is a deuterium labeled Mono-(2-ethylhexyl) phthalate (HY-W018392). Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD) .

HY-12756A

E6446 dihydrochloride 1 Publications Verification
E6446 dihydrochloride is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 dihydrochloride is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 dihydrochloride also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) .

HY-12756

E6446 1 Publications Verification	Toll-like Receptor (TLR) Stearoyl-CoA Desaturase (SCD)	Metabolic Disease Inflammation/Immunology
E6446 is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) .

HY-143862

Pparδ agonist 7	PPAR	Metabolic Disease
Pparδ agonist 7 is a potent agonist of Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ agonist 7 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2019105234A1, compound TM4) .

HY-143863

PPARδ agonist 8	PPAR	Metabolic Disease
Pparδ agonist 8 is a potent agonist of Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ agonist 8 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2021169769A1, compound TM2) .

HY-130437

p-nitro-Pifithrin-α	MDM-2/p53 TGF-β Receptor Caspase	Infection Metabolic Disease
p-nitro-Pifithrin-α, a cell-permeable analog of pifithrin-α, is a potent p53 inhibitor. p-nitro-Pifithrin-α suppresses p53-mediated TGF-β1 expression in HK-2 cells. p-nitro-Pifithrin-α inhibits the activation of caspase-3 by Zika virus (ZIKV) strains. p-nitro-Pifithrin-α attenuates steatosis and liver injury in mice fed a high-fat diet [4]. non-alcoholic fatty liver disease .

HY-146398

AMPK activator 6	AMPK	Metabolic Disease
AMPK activator 6 (Compound GC) reduces lipid content and activates the AMPK pathway in HepG2 and 3T3-L1 cells. AMPK activator 6 significantly suppresses the increase in triglyceride (TG) , total cholesterol (TC), low-density lipoprotein-C (LDL-C), and other biochemical indices in blood serum. AMPK activator 6 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome .

HY-155156

PF-07238025	Endogenous Metabolite	Cardiovascular Disease
PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC₅₀=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice .

HY-155157

PF-07247685	Endogenous Metabolite	Cardiovascular Disease
PF-07247685 is a BCKDC kinase (BDK) inhibitor (EC₅₀=2.2 nM). PF-07247685 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 improved cardiometabolic endpoints and improves glucose tolerance in mice .

HY-161211

HSD17B13-IN-7	17β-HSD iGluR	Metabolic Disease
HSD17B13-IN-7 (compound 1), a fluorophenol-containing compound, is a potent HSD17B13 inhibitor with IC₅₀s of 0.18 μM and 0.25 μM β-estradiol and Leukotriene B4 as substrates, respectively. HSD17B13-IN-7 is a potent N-methyl-D-aspartate (NMDA) NR2B receptor antagonist. HSD17B13-IN-7 has the potential for non-alcoholic fatty liver disease research .

PRDX3(103-112) SO3 modified, human	Ferroptosis	Metabolic Disease
PRDX3(103-112) SO3 modified, human is a marker of ferroptosis, and can be used for liver diseases study .

Cat. No.	Product Name	Category	Target	Chemical Structure